Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:40 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: Alopecia Areata
Interventions: MedJet Device with intralesional triamcinolone; Combination Product
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 6 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acupuncture, Low Back Pain
Interventions: NSAIDS, Battlefield Acupuncture, GV26 with manual tonification; Drug · Device
Lead sponsor: David Moss; Federal
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Exposure, Cardiopulmonary
Interventions: Blood Donation, Plasma Donation, Zone 2 Training, Intermittent Fasting, Surveys; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Gilbert, Arizona • Green Valley, Arizona • Tucson, Arizona

Conditions: Nonconvulsive Status Epilepticus, Seizures
Interventions: Ceribell Rapid Response EEG, Survey; Device
Lead sponsor: Ceribell Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Hepatitis C, Chronic
Interventions: GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet; Drug · Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 54
States / cities: Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more

Conditions: Hepatitis C
Interventions: ABT-072, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Waukegan, Illinois

Conditions: Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions: 68Ga-Galmydar, PET/MRI, 18F-FDG; Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: exemestane; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Infection, Human Immunodeficiency Virus
Interventions: CAB, RIF; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Loperamide HCl 2 mg and simethicone 125 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Obesity
Interventions: Low-Carbohydrate Diet, Intermittent Energy Restriction, Hunger Training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy
Interventions: BI 691751 fasted, BI 691751 after high fat breakfast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metabolic Complications
Interventions: Metformin, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Fontan Physiology
Interventions: Small volume breath and fast breathing rate for 5 minutes, Large volume breath and slow breathing rate for 5 minutes; Other
Lead sponsor: Stanford University; Other
Eligibility: 2 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anxiety, Stress, Mood, Motivation, Well-Being, Psychological, Self Esteem
Interventions: Rapid Planning Method (RPM), Journaling; Behavioral
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 19 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Myeloid Leukemia
Interventions: ASTX727, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 18 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: LY2157299; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Inappropriate Sinus Tachycardia
Interventions: electrophysiology study and radiofrequency ablation; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Medullary Thyroid Cancer, Colon Cancer
Interventions: Tumor Genomic Analysis; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pharmacokinetics
Interventions: Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Obstructive Sleep Apnea
Interventions: Ultrasound Exam, Polysomnography; Device
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Healthy Volunteer
Interventions: RO4917523; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Spinal Cord Injury, Vitamin D Deficiency
Interventions: Vitamin D3; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Epilepsy, Alzheimer Disease, Epilepsy Intractable
Interventions: NPT 2042 (Reference formula/Formulation 1), NPT 2042 (Test formula/Formulation 2); Drug
Lead sponsor: NeuroPro Therapeutics, Inc.; Industry
Eligibility: 19 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Accessible Acupuncture for the Warrior With Acute Low Back Pain

Firefighter Collaborative Research Project

Does Use of Rapid Response EEG Impact Clinical Decision Making

Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection

Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072

Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

Testing the Effect of Multiple Weight Management Modalities for Chronic Disease Risk Reduction in a Clinical Setting

Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects

Metformin for the Prevention of the Metabolic Side-effects of Zyprexa

Effects of Different Tidal Volume Ventilation Strategies on Fontan Flow and Hemodynamics

Efficacy of the Tony Robbins Rapid Planning Method (RPM)

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Study of LY2157299 in Healthy Participants

Ablation of Inappropriate Sinus Tachycardia

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

Ultrasound Against Obstructive Sleep Apnea

A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers

Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI

Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042